Loading
Cytek Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by McCombe William D., was filed 03 Jun 2025.
Insider Decl.
563
Thresholds
n/a
Buy Volume
€88M
27 ops. · all time
Sell Volume
€10M
75 ops. · all time
Who traded when
BuySaleWilliam D. McCombe1 buy
Since the insiders bought
- +27.4%Entry US$3.40 · Close at T+365 US$4.33
- -21.6%Entry US$12.11 · Close at T+365 US$9.50
- -36.2%Entry US$19.85 · Close at T+365 US$12.66
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Cytek Biosciences, Inc. Buy (bullish), based on 4 analysts. Average price target: US$5.56.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,017 of 26,246 companies
27.5
score / 100
Value25
Quality30
FCF yld-1.2%
Earn yld-9.3%
EV/EBITDA·
ROE-23%
Gross mgn52%
Net mgn-33%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$5.50
Analyst consensus
4 analystsBuy
US$4.75Target US$5.56(+1%)US$7.50
Income statement
RevenueUS$201.5M
Gross profitUS$104.5M52% margin
EBITDA-US$17.4M-9% margin
Net income-US$66.5M-39.0% margin
Valuation
PER (forward)78.6x
P/Book2.2x
Beta1.16
Balance sheet & cash
Market capUS$714.9M
Total debtUS$23.7M
Free Cash Flow-US$8.9M
Debt / Equity8%
Profitability & ownership
ROE-23.0%
ROA-6.3%
% insiders8.5%
% institutions62.8%
Last declaration on 20 August 2026
Declarations563 total
6,107 sharesCommon StockSEC:0001337252-26-000005:0
3,086 sharesCommon StockSEC:0001181190-26-000007:0
2,181 sharesCommon StockSEC:0001515140-26-000005:0
11,781 sharesCommon StockSEC:0001872873-26-000006:0
2,869 shares@ US$4.670.0018% mcap0.3% of flowCommon StockSEC:0001872873-26-000006:1
22,100 sharesCommon StockSEC:0001872873-26-000006:2
5,382 shares@ US$4.670.0033% mcap0.6% of flowCommon StockSEC:0001872873-26-000006:3
29,002 sharesCommon StockSEC:0001872873-26-000006:4
7,062 shares@ US$4.670.0044% mcap0.7% of flowCommon StockSEC:0001872873-26-000006:5
57,212 sharesCommon StockSEC:0001872873-26-000006:6
20,956 shares@ US$4.670.013% mcap2.2% of flowCommon StockSEC:0001872873-26-000006:7
7,363 sharesCommon StockSEC:0001874041-26-000009:0
1,778 shares@ US$4.670.0011% mcap0.2% of flowCommon StockSEC:0001874041-26-000009:1
5,525 sharesCommon StockSEC:0001874041-26-000009:2
1,346 shares@ US$4.670.0008% mcap0.2% of flowCommon StockSEC:0001874041-26-000009:3
6,162 sharesCommon StockSEC:0001874041-26-000009:4
1,501 shares@ US$4.670.0009% mcap0.2% of flowCommon StockSEC:0001874041-26-000009:5
14,220 sharesCommon StockSEC:0001874041-26-000009:6
6,320 sharesCommon StockSEC:0001878824-26-000004:0
2,111 shares@ US$4.670.0013% mcap6.4% of flowCommon StockSEC:0001878824-26-000004:1
13,051 sharesCommon StockSEC:0001878824-26-000004:2
4,392 shares@ US$4.670.0027% mcap13.3% of flowCommon StockSEC:0001878824-26-000004:3
16,049 sharesCommon StockSEC:0001878824-26-000004:4
5,401 shares@ US$4.670.0034% mcap16.4% of flowCommon StockSEC:0001878824-26-000004:5
3,463 shares@ US$4.670.0022% mcap0.4% of flowCommon StockSEC:0001874041-26-000009:7
25 of 563 declarations
About Cytek Biosciences, Inc.
On July 27, 2021, RA Capital Management, L.P., filed as a director of Cytek Biosciences, Inc. (Healthcare & Pharma), bought EUR 39,724,995, the largest purchase in the record. From July 22 to July 27, 2021, 5 filers bought EUR 42,581,487 worth, and RA Capital Management bought again EUR 3,918,298 on March 7, 2022 and EUR 3,912,617 on March 11, 2022. The 27 purchases total EUR 87,567,900 (median EUR 2,160,180), or 26% of open-market trades; 6 cluster-buy filings are recorded.
The 75 sales weigh EUR 10,250,826, with a median of EUR 151,621. The three largest are by Wenbin Jiang (President and CEO): EUR 302,175 on October 7, 2022, EUR 297,317 on November 7, 2022 and EUR 295,951 on August 8, 2022.
Read moreShow less
Of 563 filings from 19 filers, 238 are option exercises and 209 are grants. Ming Yan (Chief Technology Officer) files 126, of which 33 sales, Wenbin Jiang 117 and Valerie Barnett (Chief Legal Officer) 82. The year 2025 has 135 filings. The last twelve months total 103, with no purchase and no sale. Insiders hold 8.5% of the capital, valued at USD 682.4 million. The 27 purchases tracked at 90 days show a median of -18.5% with 26% of cases positive, recorded past results, not a forecast.
